?? Pillar Biosciences is thrilled to announce our strategic partnership with Hamilton Company for NGS Application Development and Co-Marketing. Together, we are driving the automation of rapid NGS testing, making it faster, more accessible, and cost-effective for labs worldwide. Hamilton will develop automation scripts for Pillar's RUO NGS panels on their Microlab? STAR? Liquid Handling Systems, starting with the oncoReveal? Essential MPN panel. By combining Pillar Biosciences' innovative simplicity and speed with Hamilton's global reach and automation expertise, we are breaking barriers to localized NGS adoption — empowering more labs to access critical tumor profiling results faster and more cost-effectively. ?? Learn more about this strategic partnership here: https://lnkd.in/ep2xipBq
Pillar Biosciences Incorporated
生物技术
Natick，Massachusetts 8,142 位关注者
Localizing NGS testing to empower decisions across the entire healthcare journey for everyone, everywhere
关于我们
As the leader in Decision Medicine?, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.
- 网站
-
https://pillarbiosci.com
Pillar Biosciences Incorporated的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Natick，Massachusetts
- 类型
- 私人持股
- 创立
- 2014
- 领域
- NGS、Target Enrichment、Molecular Pathology、cell-free DNA analysis、Liquid Biopsy、Multiplex PCR、Personalized Medicine和Precision Medicine
地点
-
主要
获取路线
9 Strathmore Rd
US，Massachusetts，Natick，01760
Pillar Biosciences Incorporated员工
-
Jamie Lim
Associate Director Project Management at Pillar Bio
-
Christopher J. Jowett
Inspirational Sales & Marketing Leader l Go-to-Market Strategy Development & Execution l Global Product Launch l Molecular Diagnostics & Life…
-
Gang Song
Chairman of the Board at Pillar Biosciences Incorporated
-
Susana Guedes
Bringing NGS testing to everybody everywhere
动态
-
We look forward to working closely together with the GenomOncology team to help accelerate rapid, localized NGS testing.
We are thrilled to announce our strategic co-marketing partnership with Pillar Biosciences Incorporated! This collaboration merges GenomOncology's advanced clinical decision support platform with Pillar's state-of-the-art NGS testing solutions. Together, we're revolutionizing how oncologists access and interpret genomic data to make precise treatment decisions. Our integrated solution streamlines the path from NGS testing to actionable clinical insights, enabling faster, more informed treatment decisions for cancer patients. This partnership represents a significant step forward in making precision oncology more accessible and efficient for healthcare providers worldwide. #PrecisionOncology #PrecisionMedicine #NGS #CancerGenomics #Oncology #BioinformaticsSolutions #CancerCare #PersonalizedMedicine #DigitalHealth #MolecularDiagnostics #ClinicalGenomics #BiotechNews #HealthTech #CancerResearch #GenomicMedicine
-
Pillar Biosciences is heading to the 9th Annual Liquid Biopsy for Precision Oncology Summit in San Diego next week, February 18-20. Stop by Booth 5 to learn how we're transforming precision medicine and driving more efficient, accessible next-generation sequencing testing for liquid biopsy and beyond.
-
-
New White Paper, Now Live! Check out our latest white paper: "Targeted NGS as a Frontline Strategy to Accelerate the Precision Treatment of Solid and Heme Tumors". Discover how leading cancer centers are using targeted NGS to: - Streamline tumor profiling - Achieve rapid turnaround times - Consolidate biomarker testing Featuring insights from experts at MSK and USC Keck Hospital. Don't miss this opportunity to learn about cutting-edge approaches and advancing our mission of Decision Medicine? ??Download the white paper now!?https://lnkd.in/eGMmZpUS
-
-
?? In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine? and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We've made substantial advancements and improved access to precision oncology solutions globally. As we step into 2025, let's celebrate the milestones we've achieved together in 2024. ? Highlights include: * Innovative product launches * Strategic partnerships that have expanded our reach * Significant contributions and advancements in Next-Generation Sequencing (NGS) technology and oncology diagnostics. Join us in looking back at our accomplishments and envisioning an even brighter future. Check out our full Year in Review to see how we're shaping the future of biosciences! ?? Read more here: https://lnkd.in/eacR-t2S
-
-
Pillar Biosciences Incorporated has entered into a licensing agreement for Memorial Sloan Kettering Cancer Center's OncoKB? Precision Medicine Knowledgebase. OncoKB??is the first somatic human variant database to receive FDA recognition. It contains information about the biological effects and possible treatment implications of specific cancer gene alterations.? The strategic licensing agreement enables immediate extension of the capability of Pillar Biosciences PiVAT? bioinformatics platform for seamless patient genomic reporting through linkage to OncoKB?. https://lnkd.in/gR9H2JpX
-
It's not too late to register for our upcoming December webinar hosted by GenomeWeb this Thursday, December 5th at 8 am PST. Join us for an insightful session with Dr. Mark Ewalt, MD and @Dr. Pamela Ward, PhD as they explore Pillar Biosciences' oncoReveal Nexus 21 Gene panel and the clinical need for a rapid targeted NGS panel as a complement to CGP. Discover real-world implementation data from USC Keck Hospital, Norris Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center. Don't miss this opportunity to revolutionize your lab's cancer diagnostics! Register now: https://lnkd.in/e6KMEhet
-
-
??Exciting Webinar, Next Thursday, December 5th! ?? Join us on Thursday, December 5th for an insightful session with Dr. Mark Ewalt, MD and Dr. Pamela Ward, PhD as they explore targeted NGS as a front-line strategy to accelerate the delivery of precision medicine for solid and heme tumors. ??Discover real-world implementation data from USC Keck Hospital, Norris Comprehensive Cancer Center, and MSK. ??Learn how rapid targeted NGS testing can be leveraged as a tool to help sub-select and inform which patients should have follow-on CGP testing. ??Understand how Pillar Biosciences' oncoReveal Nexus 21 Gene panel can be used by laboratories to streamline the use of single-gene PCR testing. Register today: https://lnkd.in/e6KMEhet
-
-
Did you miss any of our scientific poster presentations or do you want to learn more about the scientific data presented? Poster and abstract summaries of the research presented in the ten scientific posters featuring Pillar Biosciences Incorporated will be available at our #AMP2024 Booth #1307. Please stop by to ask questions or for more information.
-
Explore ten scientific posters highlighting Pillar Biosciences' oncoReveal suite of kitted NGS solutions this Friday and Saturday at #AMP2024. Topics covered include: ? Clinical validation of oncoReveal CDx, our FDA-approved pan-cancer solid tumor IVD assay ? Validation of our rapid, targeted NGS panels ? Performance insights on our Essential MPN Panel ? Automation of our panels using state-of-the-art library prep systems Join us to see how Pillar Biosciences is empowering laboratories with simple, fast, and accurate NGS solutions. See the full schedule below.
-